clinical pharmacokinetics 2013
DESCRIPTION
efTRANSCRIPT
![Page 1: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/1.jpg)
Clinical Pharmacokinetics
Dr. Norul Badriah Hassan Jabatan Farmakologi
Pusat Pengajian Sains Perubatan Universiti Sains Malaysia
![Page 2: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/2.jpg)
Objectives
1. Drug-Response Relationship
2. Why we need to study pharmacokinetics?
3. Absorption
4. Sites of Drug Administration
5. Bioavailability and factors affecting bioavailability
6. Absorption in children and elderly
7. Distribution
8. Distribution in children and elderly
9. Metabolism
10. Metabolism in children and elderly
11. Excretion
12. Excretion in children and elderly
![Page 3: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/3.jpg)
Pharmacokinetics
• Study of the movement of drugs through the body.
• Pharmacokinetics determine the time course of drug concentrations in serum or plasma as well as in tissues and body fluids
![Page 4: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/4.jpg)
Pharmacokinetics
•Absorption
•Distribution
•Metabolism
• Excretion
![Page 5: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/5.jpg)
Site of
ActionDosage Effects
Plasma
Concen.
Pharmacokinetics Pharmacodynamics
what the body does to the drug
what the drug does to the body
![Page 6: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/6.jpg)
Drug-Response Relationship
Relationship between dose of a drug and response produced by that drug
Generally if there is more dose, then there will be more drug-receptor complex and more response
But when the maximum response is produced by the drug, then there will be no more increase of response even after administration of more dose.
![Page 7: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/7.jpg)
Dose & Response D
rug C
oncentr
ation
Therapeutic Window
Therapeutic Response Adverse Effects
![Page 8: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/8.jpg)
Dose-Response Relationship
• Potency of A is more than B (less dose is needed to produce same response)
• Efficacy of both same (max response same).
![Page 9: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/9.jpg)
Pharmacokinetics
![Page 10: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/10.jpg)
Why we need to study pharmacokinetics?
• Compare and select appropriate drugs
• Mode of administration
• Dosage adjustment
![Page 11: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/11.jpg)
![Page 12: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/12.jpg)
Sites of Drug Administration
• GI tract
• Artery
• Peripheral vein
• Muscle
• Subcutaneous tissue
• Lung
![Page 13: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/13.jpg)
Bioavailability
• Percentage or fraction of
administered dose that reaches systemic circulation of patient.
Bioavailability = AUC (oral)
AUC (intravenous)
![Page 14: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/14.jpg)
Bioavailability
1. Dissolution
2. Absorption
3. Chemical form (e.g. salt)
4. Dosage form (tablet, solution)
5. Route of administration
6. Stability of active ingredient in GI tract
7. Extent of drug metabolism
![Page 15: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/15.jpg)
Oral Bioavailability
Dose
Destroyed
in gut
Not
absorbed
Destroyed
by gut wall
Destroyed
by liver
to
systemic
circulation
![Page 16: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/16.jpg)
Oral bioavailability
Drug Foral (%)
Gentamicin
Verapamil
Lignocaine
Propranolol
Digoxin
Phenytoin
Valproate
< 5
22
35
36
75
98
100
![Page 17: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/17.jpg)
Plasma concentration-time
relationship after a single oral dose
![Page 18: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/18.jpg)
Effect of Food on Bioavailability
Grapefruit juice:
• increases bioavailability:
☻felodipine - 200%
☻nifedipine - 57%
☻verapamil - 36%
![Page 19: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/19.jpg)
Effect of Food on Bioavailability
Grapefruit juice:
• Alter the pharmacokinetics of oral medications by different mechanisms:
☻ inhibit CYP3A4 irreversibly in intestinal apical enterocytes and hepatocytes.
☻ Inhibition of the P-glycoprotein in intestinal enterocytes. ↑ drug amount in systemic circulation.
• This inhibitory effect can last up to 72 hours after final
consumption of the grapefruit juice.
![Page 20: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/20.jpg)
Effect of Food on Bioavailability
• Other fruits which inhibit the CYP3A4 enzyme system:
• Seville orange juice • Pimelo
• common orange juice (30% of the inhibitory
effect compared to grapefruit)
![Page 21: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/21.jpg)
Drugs Known to Have Potentially Serious Interactions with
Grapefruit Products
Antiepileptics Carbamazepine
Antidepressants Sertaline, buspirone,
clomipramine
Benzodiazepines Diazepam
Calcium channel blocker Felodipine, nifedipine,
nimodipine, verapamil
Antiretroviral agents Saquinavir, indinavir
Statins Simvastatin, lovastatin,
atorvastatin
Cytotoxic drugs Cyclosporin, tacrolimus,
Antiarrhythmics Amiodarone
Miscellaneous Methadone, sildenafil
Pillai et al, South Med J. 2009
![Page 22: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/22.jpg)
Absorption in Children
Infant- slower compared to older children and adults:
• Prolong GI emptying time
• Unpredictable gastric peristalsis
• Delayed time to peak concentrations
![Page 23: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/23.jpg)
Absorption in Children
• Gastric pH values: 1 to 3 within 24 hours after birth neutral by 1 week of age slowly decline over 2 to 3 years to adult values.
• These changes may result in: greater absorption of basic drugs, e.g amoxicillin, erythromycin, and penicillin G.
reducing absorption of weak acidic drugs, including phenobarbital.
![Page 24: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/24.jpg)
Cmax
![Page 25: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/25.jpg)
Distribution
• Refers to transport of drugs to body compartment and the time required for the drug to reach those locations.
• Vd : Volume of distribution
(liters or L/kg).
![Page 26: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/26.jpg)
Distribution
Factors affecting drug transport:
• Protein binding
• Body fluids
• Membrane transport/permeability
• Blood and tissue hemodynamics
![Page 27: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/27.jpg)
Distribution
Determinants of drug movement to maintain equilibrium:
• Disease states
• Drug lipid solubility
• Characteristics of body tissues
• Regional pH differences
• Protein binding
![Page 28: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/28.jpg)
Volume of Distribution
A measure of the tendency of a drug to move out of the blood plasma to some other site.
![Page 29: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/29.jpg)
D
V
C = D/V
V = D/C
Concentration of
a drug in the
plasma
Total amount of
the drug in the
body
Volume of Distribution
![Page 30: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/30.jpg)
D
V
Average population Vd = 1 L/kg Desired
Plasma concentration = 15 mg/L
Required loading dose = 15 mg/kg.
Volume of Distribution
Vd (L/Kg) =Amount of drug (mg)
Css (mg/L)
Drugs with extensive extraplasma
distribution seem to have large Vd values.
![Page 31: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/31.jpg)
D
V
D = 50 mg
C = 2.5 mg/L
V = D/C
= 50mg /
2.5mg/L
= 20 Litres
Volume of Distribution
Vd (L/Kg) =Amount of drug (mg)
Css (mg/L)
![Page 32: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/32.jpg)
Loading Dose As with infusions, a loading dose may be required to produce
therapeutically effective blood levels without delay.
With loading dose (extra large initial dose)
![Page 33: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/33.jpg)
Immediately effective treatment
![Page 34: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/34.jpg)
Divided doses
![Page 35: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/35.jpg)
Volumes of distribution (In litres for average 70 Kg adult)
Warfarin 7
Gentamicin 16
Theophylline 35
Cimetidine 140
Digoxin 510
Mianserin 910
Quinacrine 50,000
Small vol. Mainly in
plasma little in
tissues.
Medium volume.
Similar concent in
plasma and tissues
Large volume.
Mainly in tissues,
little in plasma.
![Page 36: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/36.jpg)
36
Amount
eliminated << 1
dose
Amount
eliminated < 1
dose
Amount
eliminated = 1
dose
Steady state
![Page 37: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/37.jpg)
Css,max = “Peak”
Css (Average)
Css,min = “Trough”
Concentrations at
Steady State
![Page 38: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/38.jpg)
Free Vs Bound Drug
• Drug bound to protein is inactive
• Only unbound or free drug is pharmacologically active.
![Page 39: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/39.jpg)
Free Versus Bound Drug
Major drug binding proteins in serum:
• Albumin,
• 1-acid glycoprotein
• Lipoproteins
In uremia
↑ free drug concentration
liver disease
hypoalbuminemia
![Page 40: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/40.jpg)
Protein Binding of Commonly Monitored
Therapeutic Drugs
Drug Protein Binding
(%)
Protein Type
Amikacin <5 No
Kanamycin <5 No
Ethosuximide 0 No
Procainamide 10–15 Albumin
Theophylline 40 Albumin
Phenobarb 40 Albumin
Phenytoin 90 Albumin
Carbamazepine 80 Albumin
Valproic acid 90–95 Albumin
Primidone 15 Albumin
Digoxin 25 Albumin
Quinidine 80 1-acid glycoprotein
Lidocaine 60–80 1-acid glycoprotein
Cyclosporine 98 Lipoproteins
A. Dasgupta Handbook of Drug Monitoring Methods © Humana Press Inc., Totowa, NJ
![Page 41: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/41.jpg)
Pathophysiological Conditions that Reduce
Albumin Concentration Leading to an Increase in Free Fraction of Acidic Drugs
Uremia
Pregnancy
Intensive care unit patients
Trauma patients
Liver disease
Hyperthyroidism
Burn patient
Elderly (> 75years)
Cirrhosis
Malnutrition
AIDS patients
Reduced Albumin Concentrations
A. Dasgupta Handbook of Drug Monitoring Methods © Humana Press Inc., Totowa, NJ
![Page 42: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/42.jpg)
Distribution in Elderly
Fat soluble (lipophilic)
Increased Vd in older persons because they have greater fat stores.
Longer time to reach a steady-state
Longer elimination from the body.
Examples of fat-soluble drugs: diazepam, thiopental
![Page 43: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/43.jpg)
Distribution in Elderly
• Vd also influenced by protein binding.
• Albumin is often decreased in older patients
• Higher proportion of drug is unbound (free) and pharmacologically active.
• eg. ceftriaxone, diazepam, lorazepam, phenytoin, valproic acid, and warfarin.
![Page 44: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/44.jpg)
Distribution in Children
Total Body Water and Extracellular Fluid Volume • Expanded total body water values relative to body weight are
observed in newborns,infants, and children compared with adults: 80% total body weight in premature infants 70 to 75% in newborns 50 to 60% in adults
• Neonates and young infants also have a greater extracellular fluid
compartment relative to body weight compared with adults.
• For watersoluble drugs demonstrating distribution through total body water, larger doses will be required in infants to achieve comparable serum concentrations to those achieved in adults.
• e.g aminoglycosides, penicillins, and cephalosporins,
![Page 45: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/45.jpg)
Metabolism
• Defined as chemical modification of a drug in a biologic environment.
• Also referred as drug biotransformation or drug detoxification.
![Page 46: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/46.jpg)
Metabolism
• Liver - most common site of drug metabolism
• Metabolic conversion also can take place in:
intestinal wall lungs skin kidneys other organs
![Page 47: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/47.jpg)
Metabolism
• Most drugs undergo metabolism.
• Only few excreted unchanged in urine.
e.g. Acetazolamide Penicillin G
![Page 48: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/48.jpg)
First-Pass Effect
• Some drugs may be extensively metabolised by the liver before reaching systemic circulation
• First pass refers to metabolism by the liver as a drug passes through the liver via portal vein following absorption
![Page 49: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/49.jpg)
Metabolism in Children
• Both Phase I and II reactions mature over time.
• Phase I reactions generally mature by 1 year of age.
• Phase II processes mature at a slower rate,
• E.g - glucuronidation activity by 3 to 4 years of age.
• CYP activity is present at 30 to 60% of adult values in infancy.
![Page 50: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/50.jpg)
Metabolism in Elderly
• Aging affects the liver by decreasing liver blood flow, liver size & mass.
• Consequently, in the older patient the metabolic clearance of drugs by the liver may be reduced.
![Page 51: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/51.jpg)
Excretion
• Excretion refers to a drug’s final route(s) of exit from the body.
• For most drugs, this involves elimination by the kidney as either the parent compound or as a metabolite or metabolites.
• Terms used to express excretion are drug’s half-life (t1/2) and its clearance.
![Page 52: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/52.jpg)
Half-Life
• A drug’s half-life is the time it takes for its plasma or serum concentration to decline by 50%,
e.g. from 20 µg/mL to 10 µg/mL.
• Expressed in hours.
• Steady state is reached when the amount of drug entering the systemic circulation is equal to the amount being eliminated.
• For a drug administered on a regular basis, 95% of steady state in the body is achieved after five half-lives of the drug.
![Page 53: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/53.jpg)
Half-Life
![Page 54: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/54.jpg)
Linear vs non-linear pk
• First order kinetics = linear
Rate of change in drug concentration is
proportional to drug concentration
• Zero order kinetics = non-linear
Michealis-Menten Equation- capacity limited
kinetics
![Page 55: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/55.jpg)
For most drugs [Expansion of the relevant part of the graph]
Drug concentration
Elimination
rate Graph would start to curve if
we went to much higher
concentrations and began to
saturate the enzyme.
![Page 56: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/56.jpg)
For CERTAIN drugs
Drug concentration
Elimination
rate
Highest concentrations actually seen in
real therapeutic use.
Too little to saturate the enzyme.
Almost no curvature.
![Page 57: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/57.jpg)
Rate of
eliminat’n
Rate of
eliminat’n
Blood drug conc Blood drug conc
Linear kinetics
(most drugs)
Non-linear
kinetics
(e.g. phenytoin)
![Page 58: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/58.jpg)
NON-LINEAR KINETICS
There are a small number of drugs where
concentrations seen in real life use are high
enough to saturate the eliminating enzymes.
Phenytoin - The only case of real clinical
significance
•Salicylates
•Ethanol
Theophylline may approach saturation but, in
practice, it can be treated as following linear
kinetics.
![Page 59: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/59.jpg)
Factors Causing Non-Linear Kinetics
Absorption
• Poor aqueous solubility/slow dissolution
(griseofulvin)
• Site specific absorption along GI tract (phenytoin)
• Carrier mediated absorption (riboflavin)
![Page 60: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/60.jpg)
Factors Causing Non-Linear Kinetics
Absorption
• P-glycoprotein efflux in intestinal epithelial cells (cyclosporin A)
• Saturable first pass effect by the intestine and/or liver (propranolol).
• Dose/time-dependent changes in GI physiology including gastric emptying, GI motility & GI blood flow rate.
![Page 61: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/61.jpg)
Factors Causing Non-Linear Kinetics
Distribution
• Non-linear plasma protein binding (valproic
acid)
• Carrier-mediated membrane transport (thiamine)
• Non-linear tissue binding (prednisolone)
![Page 62: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/62.jpg)
Factors Causing Non-Linear Kinetics
Metabolism
• Saturable metabolism (ethanol)
• Product inhibition (dicoumarol)
• Co-substrate depletion (acetaminophen)
• Nonlinear plasma protein binding (prednisolone)
• Autoinduction
![Page 63: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/63.jpg)
Factors Causing Non-Linear Kinetics
Excretion
• Nonlinear protein binding and/or glomerular
filtration (naproxen)
• Carrier-mediated tubular excretion (cimetidine)/reabsorption (riboflavin)
• Carrier-mediated biliary excretion (iodipamide)
![Page 64: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/64.jpg)
Excretion in Children
• Glomerular filtration function is dramatically reduced in newborns
• Greater immaturity in premature infants when compared with full-term infants
• Increases in glomerular filtration rate (GFR) occur in the first weeks of life, reaching 50 to 60% of adult function by the third week of life, and adult values by 8 to 12 months of age.
• By 3 to 6 years of life, GFR values exceed adult values.
• Therefore, drugs dependent on glomerular filtration will show reduced drug clearance through early infancy, more evident in premature infants, and likely require dosage reduction.
• During early childhood, higher daily doses are likely when corrected for weight and in comparison with adult doses because of increased GFR.
![Page 65: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/65.jpg)
Clearance in the Elderly
• Decline in renal function with age, even in the absence of renal disease
• Increased Vd
• Larger drug storage reservoirs
• Decreased drug clearance
• Prolong drug half-lives and lead to increased plasma drug concentrations in older people.
![Page 66: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/66.jpg)
Creatinine in Elderly
• Serum creatinine - not accurate reflection of creatinine clearance in elderly patients.
• Decline in lean muscle mass cause reduced production of creatinine.
![Page 67: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/67.jpg)
Acknowledgements
• Dr. Mohd Suhaimi Ab Wahab
• Dr. Ruzilawati Abu Bakar
![Page 68: Clinical Pharmacokinetics 2013](https://reader033.vdocument.in/reader033/viewer/2022050819/55cf9043550346703ba472e0/html5/thumbnails/68.jpg)
Suggested Readings
• Michael E. Winter, Basic Clinical Pharmacokinetics,
4th ed. Lippincott Williams & Wilkins, Philadelphia
• Thomas N. Tozer & Malcolm Rowland, Introduction to Pharmacokinetics and pharmacodynamics:
The quantitative basis of drug therapy.
Lippincott Williams & Wilkins, Philadelphia